Biotech Entrepreneur Secures $30M to Launch Preventive, a Public‑Benefit Gene‑Editing Company

Why It Matters

If successful, Preventive could reshape preventive medicine but also intensify ethical and regulatory scrutiny over germline editing, while Still Bright’s approach could reduce copper's carbon footprint and improve supply resilience, addressing climate and industrial demand pressures.

Deal Summary

A West Coast biotech entrepreneur announced the formation of Preventive, a public‑benefit company focused on heritable genome editing, after raising $30 million. The funding will support research into safely creating genetically edited babies to prevent disease. The announcement was made in a November 3, 2025 article.